SAN FRANCISCO – Savonix is hoping to change the way cognitive function is measured with its new digital cognitive assessment, Savonix Mobile.
“It all happens in the app,” said Mylea Charvat, Ph.D., Savonix founder. “The results are immediately available to the patient without the need for a trip to a neuropsychologist for two days of testing.”
The user is prescribed a code to the app from their physician, and the test can be taken right at home, or anywhere, on a tablet or smartphone. The app tests instant verbal memory, focus, impulse control, spatial memory and emotion indentification.
After the test is taken, Savonix delivers personalized results in percentile scores and gives recommendations. Scores the user might need to pay attention to are flagged.
Charvat said that cognitive data is vital to patients with COPD, breast cancer, diabetes and other chronic conditions. Cognition scores can also screen for Alzheimer’s Disease and dementia.
“Cognition is one of the top three predictors of a treatment being successful,” Charvat said. “If the patient doesn’t understand the treatment instructions, they won’t be able to follow the plan correctly and that could be dangerous. Even mild cognitive impairment can have profound implications on successful treatment or adherence.”
Compared to thousands of dollars for the traditional pen and paper cognitive testing, Savonix Mobile costs about $40 per test. Charvat said that the app can be a good first step for the user, who can go for further neuropsychological testing if their scores indicate such a recommendation.
Currently, Savonix Mobile is marketed to clinical providers, and Charvat said there has been some interest from the pharmaceutical space.
“I see this making the biggest difference in the clinical care sector,” Charvat said. “We’re going to really start building relationships with clinical providers and scaling the assessment.”
Charvat said the app also has the ability to collect data on a population health level, including pattern matching and predictive analytics.
“We can start to account for cognition more broadly and look at how it affects everything,” Charvat said.